<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04444843</url>
  </required_header>
  <id_info>
    <org_study_id>ML40754</org_study_id>
    <nct_id>NCT04444843</nct_id>
  </id_info>
  <brief_title>Risk Factors of Chinese Kidney Transplant Recipients DSA Based on MPA Immunosuppressive Regimen</brief_title>
  <official_title>A Multicenter Clinical Trial: Risk Factors of Chinese Kidney Transplant Recipients DSA Based on MPA Immunosuppressive Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital Xi'an Jiaotong University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      THE INCIDENCE AND INFLUENTIAL FACTORS OF DSA IN CHINESE RENAL TRANSPLANT RECIPIENTS WITH
      MPA-BASED IMMUNOSUPPRESSIVE REGIMEN： A MULTI-CENTER CLINICAL STUDY (TIAIFOD STUDY)

      Study procedure Investigators at participating centers will identify patients fulfilling
      inclusion criteria and do not violate any exclusion criteria. Informed consent will be
      obtained upon entry into the study according to national regulations. Patients will be
      enrolled into the study and clinical data of patient history will be collected. Clinical data
      will be collected prospectively up to a total period of 12 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Medical history and Kidney transplantation This will include age at transplantation, gender,
      race, weight, height of both recipient and donor; Recipients: previous history ,BMI ,primary
      kidney disease including biopsy proven diagnosis (if present), historic dialysis，pregnancy
      history (female). Donor: the catalogue (DCD,DBD,DBCD), ECD or not，the cause of death,
      received CPR or not; zero biopsy results if done, ABO blood type match, HLA-MM, cold and warm
      ischemic time.

      Clinical data at baseline and 12months follow up period:

      Clinical assessments, laboratory, comorbidity, immunosuppressive therapy, and selected
      concomitant therapy (anti-hypertension anti-hyperlipidemics, anti-diabetics and drugs known
      to affect renal function) will be collected at transplant day（Day 0, visit 0）and 8 subsequent
      visits scheduled Day 3, Week1, Week2, Week 4，Week 12，Week 26，Week 40，Week 52 post
      transplantation. MPA-AUC, acute rejection episodes and graft loss will be collected at visits
      scheduled Day 3, Week 1，Week 2, Week 4，Week 12， Week 26(6 month)，Week 40，Week 52 (12 month)
      post transplantation. On day 3, MPA-AUC will be tested by full time sample
      (0h,0.5h,1h,2h,3h,4h,6h,8h,10h,12h post receiving MMF). LSS (0h, 0.5h, 2h post receiving MMF)
      will be used for testing MPA-AUC on other visits. PRA will be tested on week 4, week 12, week
      26, week 52. If PRA is positive, DSA will be tested following once. All the PRA and DSA MFI
      and phenotype will be collected（including the clinical-drive test）.

      Statistical analysis:

      The primary endpoint in this study is the incidence of DSA formation in 12-months
      post-transplantation in Chinese kidney transplant recipients with MMF-based IS regimen. The
      proportion and its 95% CI will be provided.

      The influential factors of DSA formation will be estimated using logistic regression
      including relevant influential factors, where the influential factors are defined as {age,
      gender of donor / recipients recipient: BMI, blood transfusion, previous AR （before DSA
      appears）, ECD , cold ischemia time, HLA-MM, Tac trough concentration, MPA-AUC, DGF,
      introduction therapy (including use or not and the drugs )}. .

      The full MPA-AUC0-12h will be calculated using the trapezoidal rule. The calculated formula
      with Limited Sample Strategy (LSS) will be established to predict the MPA-AUC0-12h in the
      Chinese patients. Correlation coefficients will be calculated and multiple stepwise
      regression analysis will be used to determine the time points and best equation for
      evaluating MPA-AUC0-12h.

      Estimates for the time-to-event variable(s), such as Overall Survival(OS), will be obtained
      by using the Kaplan-Meier (KM) approach together with associated 95% CI.

      The other secondary endpoints will be summarized descriptively depended on the variable type.
      The comparison between patients with and without DSA-positive will be performed according to
      the variable type.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 29, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 16, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>To estimate the incidence of DSA formation during 12-months post-transplantation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To estimate the incidence of DSA formation during 12-months post-transplantation</measure>
    <time_frame>the death-censored graft survival rate at 12 month</time_frame>
    <description>incidence of DSA formation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To estimate the incidence of DSA formation during 6-months post-transplantation</measure>
    <time_frame>the death-censored graft survival rate at 6 month</time_frame>
    <description>incidence of DSA formation during 6-months post-transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate the influential factors of DSA formation</measure>
    <time_frame>the death-censored graft survival rate at 12 month</time_frame>
    <description>influential factors of DSA formation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate the association between DSA and MPA AUC</measure>
    <time_frame>the death-censored graft survival rate at 12 month</time_frame>
    <description>association between DSA and MPA AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the calculation formula for MPA-AUC with ISS using multiple regression analysis</measure>
    <time_frame>the death-censored graft survival rate at 12 month</time_frame>
    <description>explore the calculation formula for MPA-AUC with ISS using multiple regression analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate the proportion of patients experiencing AR, BPAR, ABMR and the association with DSA</measure>
    <time_frame>the death-censored graft survival rate at 12 month</time_frame>
    <description>the proportion of patients experiencing AR, BPAR, ABMR and the association with DSA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the renal function (Calculated creatinine clearance) at 12 month and association with DSA</measure>
    <time_frame>the death-censored graft survival rate at 12 month</time_frame>
    <description>enal function (Calculated creatinine clearance) at 12 month and association with DSA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate the death-censored graft survival rate at 12 month post transplantation and association with DSA</measure>
    <time_frame>the death-censored graft survival rate at 12 month</time_frame>
    <description>the death-censored graft survival rate</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Kidney Transplant Recipients</condition>
  <arm_group>
    <arm_group_label>Mycophenolate Mofetil Capsules</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The dosage of mycophenolate mofetil (CellCept) will be decided by the investigator and should be adjusted according to clinical response or therapeutic drug monitoring. It is not allowed to switch to other MPAs. When MMF is discontinued but is not switched to other MPA, the patients will be followed until the end of study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil Capsules</intervention_name>
    <description>Patients who received MMF+TAC+ Corticosteroids immunosuppressive regimen as first choice post transplantation</description>
    <arm_group_label>Mycophenolate Mofetil Capsules</arm_group_label>
    <other_name>Other MPAs</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female kidney transplant recipients from 18 to 65 years of age (including 18 &amp;
             65 years old patients)

          -  Single organ and first kidney transplant recipients from donation after citizen's
             death

          -  Patients who received MMF+TAC+ Corticosteroids immunosuppressive regimen as first
             choice post transplantation

          -  Pre-transplant PRA is negative (0%)

          -  One serum pregnancy test with a sensitivity of at least 25mlU/Ml for patients of
             childbearing potential before enrolled. A second test should be performed 8-10 days
             later. Repeat pregnancy tests should be performed during routine follow-up visits.
             Results of all pregnancy tests should be discussed with the patient. Patients should
             be instructed to consult their physician immediately should pregnancy occur. For
             patients to be included in the study, negative result must be obtained. And highly
             effective contraception for women of childbearing potential. Contraception must be
             taken before beginning study drug therapy, during therapy and for 6 weeks after the
             last dose of study medication

        Exclusion criteria:

          -  Patients who do not receive MMF

          -  Patients who are re-transplantation or multiple organ transplantation recipients

          -  Female patients who are pregnant or lactating

          -  Patients who have any form of substance abuse, psychological illness or any other
             condition, which, in the opinion of the investigator, may interfere with the patient's
             ability to understand the requirements of the study.

          -  Patients who would have received another investigational drug within 30 days preceding
             the enrollment, received prohibited immunosuppressant medications prior to transplant

          -  Patients who are using AZA, MTX, CTX or will use these drugs post-transplantation

          -  Known contraindications to TAC , corticosteroids, MMF

          -  Patients who have active peptic ulcer

          -  Patients who have severe cardiac or lung disease

          -  Patient who have active hepatica disease

          -  Patients who have a history of cancer, except successfully treated localized
             nonmelanocytic skin cancer

          -  Patients who would not be available for routine study visits or follow-up, or not
             being followed by an accredited laboratory.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wujun Xue, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>First Affiliated Hospital Xi'an Jiaotong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wujun Xue, Prof.</last_name>
    <phone>+86 13991990128</phone>
    <email>xwujun163@mail.xjtu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jin Zheng, Prof.</last_name>
    <phone>+86 18133916118</phone>
    <email>jzheng@mail.xjtu.edu.cn</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, Held PJ, Port FK. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999 Dec 2;341(23):1725-30.</citation>
    <PMID>10580071</PMID>
  </results_reference>
  <results_reference>
    <citation>Huang J, Millis JM, Mao Y, Millis MA, Sang X, Zhong S. Voluntary organ donation system adapted to Chinese cultural values and social reality. Liver Transpl. 2015 Apr;21(4):419-22. doi: 10.1002/lt.24069. Epub 2015 Feb 13.</citation>
    <PMID>25545626</PMID>
  </results_reference>
  <results_reference>
    <citation>Miettinen J, Peräsaari J, Lauronen J, Qvist E, Valta H, Pakarinen M, Merenmies J, Jalanko H. Donor-specific HLA antibodies and graft function in children after renal transplantation. Pediatr Nephrol. 2012 Jun;27(6):1011-9. doi: 10.1007/s00467-011-2007-6. Epub 2011 Oct 13.</citation>
    <PMID>21993970</PMID>
  </results_reference>
  <results_reference>
    <citation>Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004 Mar;4(3):378-83.</citation>
    <PMID>14961990</PMID>
  </results_reference>
  <results_reference>
    <citation>Ginevri F, Nocera A, Comoli P, Innocente A, Cioni M, Parodi A, Fontana I, Magnasco A, Nocco A, Tagliamacco A, Sementa A, Ceriolo P, Ghio L, Zecca M, Cardillo M, Garibotto G, Ghiggeri GM, Poli F. Posttransplant de novo donor-specific hla antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection. Am J Transplant. 2012 Dec;12(12):3355-62. doi: 10.1111/j.1600-6143.2012.04251.x. Epub 2012 Sep 7.</citation>
    <PMID>22959074</PMID>
  </results_reference>
  <results_reference>
    <citation>Wiebe C, Gibson IW, Blydt-Hansen TD, Karpinski M, Ho J, Storsley LJ, Goldberg A, Birk PE, Rush DN, Nickerson PW. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant. 2012 May;12(5):1157-67. doi: 10.1111/j.1600-6143.2012.04013.x. Epub 2012 Mar 19.</citation>
    <PMID>22429309</PMID>
  </results_reference>
  <results_reference>
    <citation>Everly MJ, Rebellato LM, Haisch CE, Ozawa M, Parker K, Briley KP, Catrou PG, Bolin P, Kendrick WT, Kendrick SA, Harland RC, Terasaki PI. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation. 2013 Feb 15;95(3):410-7. doi: 10.1097/TP.0b013e31827d62e3.</citation>
    <PMID>23380861</PMID>
  </results_reference>
  <results_reference>
    <citation>Hidalgo LG, Campbell PM, Sis B, Einecke G, Mengel M, Chang J, Sellares J, Reeve J, Halloran PF. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant. 2009 Nov;9(11):2532-41. doi: 10.1111/j.1600-6143.2009.02800.x.</citation>
    <PMID>19843031</PMID>
  </results_reference>
  <results_reference>
    <citation>Wiebe C, Gibson IW, Blydt-Hansen TD, Pochinco D, Birk PE, Ho J, Karpinski M, Goldberg A, Storsley L, Rush DN, Nickerson PW. Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody. Am J Transplant. 2015 Nov;15(11):2921-30. doi: 10.1111/ajt.13347. Epub 2015 Jun 10.</citation>
    <PMID>26096305</PMID>
  </results_reference>
  <results_reference>
    <citation>Cooper JE, Gralla J, Chan L, Wiseman AC. Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts. Clin Transpl. 2011:359-64.</citation>
    <PMID>22755431</PMID>
  </results_reference>
  <results_reference>
    <citation>DeVos JM, Patel SJ, Burns KM, Dilioglou S, Gaber LW, Knight RJ, Gaber AO, Land GA. De novo donor specific antibodies and patient outcomes in renal transplantation. Clin Transpl. 2011:351-8.</citation>
    <PMID>22755430</PMID>
  </results_reference>
  <results_reference>
    <citation>de Kort H, Willicombe M, Brookes P, Dominy KM, Santos-Nunez E, Galliford JW, Chan K, Taube D, McLean AG, Cook HT, Roufosse C. Microcirculation inflammation associates with outcome in renal transplant patients with de novo donor-specific antibodies. Am J Transplant. 2013 Feb;13(2):485-92. doi: 10.1111/j.1600-6143.2012.04325.x. Epub 2012 Nov 21.</citation>
    <PMID>23167441</PMID>
  </results_reference>
  <results_reference>
    <citation>Sharma A, Lewis JR, Lim WH, Palmer S, Strippoli G, Chapman JR, Alexander SI, Craig JC, Wong G. Renal transplant outcomes and de novo donor-specific anti-human leukocyte antigen antibodies: a systematic review. Nephrol Dial Transplant. 2018 Aug 1;33(8):1472-1480. doi: 10.1093/ndt/gfy077.</citation>
    <PMID>29660004</PMID>
  </results_reference>
  <results_reference>
    <citation>OʼLeary JG, Samaniego M, Barrio MC, Potena L, Zeevi A, Djamali A, Cozzi E. The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients. Transplantation. 2016 Jan;100(1):39-53. doi: 10.1097/TP.0000000000000869. Review.</citation>
    <PMID>26680372</PMID>
  </results_reference>
  <results_reference>
    <citation>Pratschke J, Dragun D, Hauser IA, Horn S, Mueller TF, Schemmer P, Thaiss F. Immunological risk assessment: The key to individualized immunosuppression after kidney transplantation. Transplant Rev (Orlando). 2016 Apr;30(2):77-84. doi: 10.1016/j.trre.2016.02.002. Epub 2016 Feb 18. Review.</citation>
    <PMID>26965071</PMID>
  </results_reference>
  <results_reference>
    <citation>Smith JM, Martz K, Blydt-Hansen TD. Pediatric kidney transplant practice patterns and outcome benchmarks, 1987-2010: a report of the North American Pediatric Renal Trials and Collaborative Studies. Pediatr Transplant. 2013 Mar;17(2):149-57. doi: 10.1111/petr.12034. Epub 2013 Jan 2.</citation>
    <PMID>23281637</PMID>
  </results_reference>
  <results_reference>
    <citation>Filler G, Lepage N. To what extent does the understanding of pharmacokinetics of mycophenolate mofetil influence its prescription. Pediatr Nephrol. 2004 Sep;19(9):962-5. Epub 2004 Jul 15. Review.</citation>
    <PMID>15257455</PMID>
  </results_reference>
  <results_reference>
    <citation>Le Meur Y, Büchler M, Thierry A, Caillard S, Villemain F, Lavaud S, Etienne I, Westeel PF, Hurault de Ligny B, Rostaing L, Thervet E, Szelag JC, Rérolle JP, Rousseau A, Touchard G, Marquet P. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant. 2007 Nov;7(11):2496-503. Epub 2007 Oct 1.</citation>
    <PMID>17908276</PMID>
  </results_reference>
  <results_reference>
    <citation>Tönshoff B, David-Neto E, Ettenger R, Filler G, van Gelder T, Goebel J, Kuypers DR, Tsai E, Vinks AA, Weber LT, Zimmerhackl LB. Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation. Transplant Rev (Orlando). 2011 Apr;25(2):78-89. doi: 10.1016/j.trre.2011.01.001. Epub 2011 Mar 30. Review.</citation>
    <PMID>21454065</PMID>
  </results_reference>
  <results_reference>
    <citation>Le Meur Y, Borrows R, Pescovitz MD, Budde K, Grinyo J, Bloom R, Gaston R, Walker RG, Kuypers D, van Gelder T, Kiberd B. Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of The Transplantation Society consensus meeting. Transplant Rev (Orlando). 2011 Apr;25(2):58-64. doi: 10.1016/j.trre.2011.01.002. Epub 2011 Mar 30.</citation>
    <PMID>21454067</PMID>
  </results_reference>
  <results_reference>
    <citation>Pawinski T, Hale M, Korecka M, Fitzsimmons WE, Shaw LM. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem. 2002 Sep;48(9):1497-504.</citation>
    <PMID>12194926</PMID>
  </results_reference>
  <results_reference>
    <citation>Magee JC, Krishnan SM, Benfield MR, Hsu DT, Shneider BL. Pediatric transplantation in the United States, 1997-2006. Am J Transplant. 2008 Apr;8(4 Pt 2):935-45. doi: 10.1111/j.1600-6143.2008.02172.x.</citation>
    <PMID>18336697</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen B, Gu Z, Chen H, Zhang W, Fen X, Cai W, Fan Q. Establishment of high-performance liquid chromatography and enzyme multiplied immunoassay technology methods for determination of free mycophenolic acid and its application in Chinese liver transplant recipients. Ther Drug Monit. 2010 Oct;32(5):653-60. doi: 10.1097/FTD.0b013e3181f01397. Erratum in: Ther Drug Monit. 2012 Aug;34(4):485.</citation>
    <PMID>20814351</PMID>
  </results_reference>
  <results_reference>
    <citation>Filler G, Todorova EK, Bax K, Alvarez-Elías AC, Huang SH, Kobrzynski MC. Minimum mycophenolic acid levels are associated with donor-specific antibody formation. Pediatr Transplant. 2016 Feb;20(1):34-8. doi: 10.1111/petr.12637. Epub 2015 Nov 21.</citation>
    <PMID>26589470</PMID>
  </results_reference>
  <results_reference>
    <citation>Metzger RA, Delmonico FL, Feng S, Port FK, Wynn JJ, Merion RM. Expanded criteria donors for kidney transplantation. Am J Transplant. 2003;3 Suppl 4:114-25. Review.</citation>
    <PMID>12694055</PMID>
  </results_reference>
  <results_reference>
    <citation>Mallon DH, Summers DM, Bradley JA, Pettigrew GJ. Defining delayed graft function after renal transplantation: simplest is best. Transplantation. 2013 Nov 27;96(10):885-9. doi: 10.1097/TP.0b013e3182a19348.</citation>
    <PMID>24056620</PMID>
  </results_reference>
  <results_reference>
    <citation>Czyżewski Ł, Wyzgał J, Czyżewska E, Kurowski A, Sierdziński J, Łabuś A, Truszewski Z, Szarpak Ł. Performance of the MDRD, CKD-EPI, and Cockcroft-Gault Formulas in Relation to Nutritional Status in Stable Renal Transplant Recipients. Transplant Proc. 2016 Jun;48(5):1494-7. doi: 10.1016/j.transproceed.2016.01.083.</citation>
    <PMID>27496434</PMID>
  </results_reference>
  <results_reference>
    <citation>Malheiro J, Tafulo S, Dias L, Martins LS, Fonseca I, Beirão I, Castro-Henriques A, Cabrita A. Analysis of preformed donor-specific anti-HLA antibodies characteristics for prediction of antibody-mediated rejection in kidney transplantation. Transpl Immunol. 2015 Mar;32(2):66-71. doi: 10.1016/j.trim.2015.01.002. Epub 2015 Feb 7.</citation>
    <PMID>25661873</PMID>
  </results_reference>
  <results_reference>
    <citation>Haas M, Loupy A, Lefaucheur C, Roufosse C, Glotz D, Seron D, Nankivell BJ, Halloran PF, Colvin RB, Akalin E, Alachkar N, Bagnasco S, Bouatou Y, Becker JU, Cornell LD, Duong van Huyen JP, Gibson IW, Kraus ES, Mannon RB, Naesens M, Nickeleit V, Nickerson P, Segev DL, Singh HK, Stegall M, Randhawa P, Racusen L, Solez K, Mengel M. The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant. 2018 Feb;18(2):293-307. doi: 10.1111/ajt.14625. Epub 2018 Jan 21.</citation>
    <PMID>29243394</PMID>
  </results_reference>
  <results_reference>
    <citation>van Gelder T, Silva HT, de Fijter JW, Budde K, Kuypers D, Tyden G, Lohmus A, Sommerer C, Hartmann A, Le Meur Y, Oellerich M, Holt DW, Tönshoff B, Keown P, Campbell S, Mamelok RD. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation. 2008 Oct 27;86(8):1043-51. doi: 10.1097/TP.0b013e318186f98a.</citation>
    <PMID>18946341</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 3, 2020</study_first_submitted>
  <study_first_submitted_qc>June 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2020</study_first_posted>
  <last_update_submitted>June 21, 2020</last_update_submitted>
  <last_update_submitted_qc>June 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>kidney transplant recipients</keyword>
  <keyword>Mycophenolate Mofetil Capsules</keyword>
  <keyword>Acute Rejection</keyword>
  <keyword>Cyclosporine</keyword>
  <keyword>Delayed graft function</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Mycophenolic Acid Area under the Curve</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

